FDA Inspection 1276175 — Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
The FDA completed an inspection of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. on June 13, 2025 in Shenzhen. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). Product area: Drugs.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI) (VAI)
- End Date
- June 13, 2025
- Fiscal Year
- 2025
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Shenzhen (China)